Published in Hepatitis Weekly, February 7th, 2000
"The ribozyme approach to inhibiting viral replication was recently applied by RPI to the hepatitis C virus (HCV)," said Ralph E. Christoffersen, RPI. "We are pleased that this patent allows us to develop and commercialize products against HBV, and apply the insights from HCV to the process."
"The application of ribozymes to the treatment of hepatitis B represents a novel and potentially effective approach to this disease," said Myron J. Tong, PhD, MD, chief of the Liver Center, Huntington Memorial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.